Novo Nordisk A/S (NYSE:NVO) Trading Up 0.7%

Novo Nordisk A/S (NYSE:NVO - Get Free Report) rose 0.7% during mid-day trading on Monday . The stock traded as high as $127.20 and last traded at $126.72. Approximately 1,109,511 shares traded hands during mid-day trading, a decline of 78% from the average daily volume of 5,077,906 shares. The stock had previously closed at $125.86.

Wall Street Analysts Forecast Growth

NVO has been the topic of several recent analyst reports. UBS Group initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a "neutral" rating on the stock. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an "overweight" rating and a $120.00 target price on the stock. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Monday, April 1st. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of "Moderate Buy" and a consensus price target of $126.25.

Novo Nordisk A/S Stock Performance

The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The company's fifty day moving average is $124.63 and its 200 day moving average is $108.66. The company has a market cap of $572.12 billion, a P/E ratio of 46.85, a price-to-earnings-growth ratio of 2.10 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The company had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. As a group, equities analysts predict that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were paid a dividend of $0.664 per share. This is a positive change from Novo Nordisk A/S's previous Semi-Annual dividend of $0.22. The ex-dividend date of this dividend was Friday, March 22nd. This represents a dividend yield of 0.9%. Novo Nordisk A/S's payout ratio is presently 49.17%.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of large investors have recently modified their holdings of the stock. Pacific Center for Financial Services lifted its position in Novo Nordisk A/S by 100.0% during the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company's stock valued at $25,000 after acquiring an additional 135 shares during the period. Copeland Capital Management LLC lifted its position in Novo Nordisk A/S by 100.0% during the 3rd quarter. Copeland Capital Management LLC now owns 282 shares of the company's stock valued at $26,000 after acquiring an additional 141 shares during the period. Bell Investment Advisors Inc lifted its position in Novo Nordisk A/S by 79.9% during the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company's stock valued at $26,000 after acquiring an additional 127 shares during the period. CNB Bank purchased a new position in Novo Nordisk A/S during the 4th quarter valued at about $26,000. Finally, Citizens National Bank Trust Department lifted its position in Novo Nordisk A/S by 100.0% during the 3rd quarter. Citizens National Bank Trust Department now owns 300 shares of the company's stock valued at $27,000 after acquiring an additional 150 shares during the period. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.